{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:06:42Z","timestamp":1791274002237,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.vaccine.2007.03.029","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T11:10:16Z","timestamp":1175598616000},"page":"4401-4409","source":"Crossref","is-referenced-by-count":25,"title":["TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A"],"prefix":"10.1016","volume":"25","author":[{"given":"Susu","family":"Zughaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2007.03.029_bib1","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1086\/315158","article-title":"The changing epidemiology of meningococcal disease in the United States, 1992\u20131996","volume":"180","author":"Rosenstein","year":"1999","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144-166.2000","article-title":"Update on meningococcal disease with emphasis on pathogenesis and clinical management","volume":"13","author":"van Deuren","year":"2000","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0891-5520(05)70273-7","article-title":"Meningococcal vaccines","volume":"15","author":"Rosenstein","year":"2001","journal-title":"Infect Dis Clin N Am"},{"issue":"24","key":"10.1016\/j.vaccine.2007.03.029_bib4","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1093\/emboj\/20.24.6937","article-title":"Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant","volume":"20","author":"Steeghs","year":"2001","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.vaccine.2007.03.029_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1086\/314927","article-title":"Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock","volume":"180","author":"Quakyi","year":"1999","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.029_bib6","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1128\/IAI.67.10.4988-4993.1999","article-title":"Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response","volume":"67","author":"Steeghs","year":"1999","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2007.03.029_bib7","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid A biosynthesis in Neisseria meningitidislpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"van der Ley","year":"2001","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib8","first-page":"113","article-title":"Teasing apart structural determinants of \u2018toxicity\u2019 and \u2018adjuvanticity\u2019: implications for meningococcal vaccine development","volume":"10","author":"Steeghs","year":"2004","journal-title":"J Endotoxin Res"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.029_bib9","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1128\/JB.184.9.2379-2388.2002","article-title":"Endotoxin of Neisseria meningitidis composed only of intact lipid A: inactivation of the meningococcal 3-deoxy-d-manno-octulosonic acid transferase","volume":"184","author":"Tzeng","year":"2002","journal-title":"J Bacteriol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1128\/IAI.72.1.371-380.2004","article-title":"Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14\/Toll-like receptor 4 pathway","volume":"72","author":"Zughaier","year":"2004","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2007.03.029_bib11","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/IAI.73.5.2940-2950.2005","article-title":"Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins","volume":"73","author":"Zughaier","year":"2005","journal-title":"Infect Immun"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.029_bib12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.vaccine.2005.09.039","article-title":"Hexa-acylation and KDO(2)-glycosylation determine the specific immunostimulatory activity of Neisseria meningitidis lipid A for human monocyte derived dendritic cells","volume":"24","author":"Zughaier","year":"2006","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2007.03.029_bib13","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1128\/jb.178.23.6677-6684.1996","article-title":"Two glycosyltransferase genes, lgtF and rfaK, constitute the lipooligosaccharide ice (inner core extension) biosynthesis operon of Neisseria meningitidis","volume":"178","author":"Kahler","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2007.03.029_bib14","doi-asserted-by":"crossref","unstructured":"York WS, Darvill AG, McNeil M, Stevenson TT, Albersheim P. Isolation and characterization of plant cell walls and cell wall components. Methods Emzymol 1985;118:3\u201340.","DOI":"10.1016\/0076-6879(86)18062-1"},{"key":"10.1016\/j.vaccine.2007.03.029_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00248674","article-title":"Structural characterization of lipid A component of Erwinia corotovora lipopolysaccharide","volume":"157","author":"Fukuoka","year":"1992","journal-title":"Arch Microbiol"},{"issue":"6675","key":"10.1016\/j.vaccine.2007.03.029_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/33046","article-title":"Meningitis bacterium is viable without endotoxin","volume":"392","author":"Steeghs","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/jlb.54.2.119","article-title":"Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells","volume":"54","author":"Park","year":"1993","journal-title":"J Leukoc Biol"},{"issue":"9316","key":"10.1016\/j.vaccine.2007.03.029_bib18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","article-title":"Development of vaccines against meningococcal disease","volume":"359","author":"Jodar","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2007.03.029_bib19","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/IAI.66.12.5939-5947.1998","article-title":"The (\u03b12\u21928)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum","volume":"66","author":"Kahler","year":"1998","journal-title":"Infect Immun"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2007.03.029_bib20","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0264-410X(02)00774-0","article-title":"Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease","volume":"21","author":"Aase","year":"2003","journal-title":"Vaccine"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2007.03.029_bib21","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2007.03.029_bib22","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1046\/j.1432-1327.2000.01204.x","article-title":"Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion","volume":"267","author":"Schromm","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2007.03.029_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000058754","article-title":"Chemical structure, molecular conformation, and bioactivity of endotoxins","volume":"74","author":"Seydel","year":"2000","journal-title":"Chem Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.1365-2567.2003.01709.x","article-title":"Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4","volume":"110","author":"Tamai","year":"2003","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.vaccine.2007.03.029_bib25","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1074\/jbc.M310760200","article-title":"Structure-activity relationship of synthetic toll-like receptor 4 agonists","volume":"279","author":"Stover","year":"2004","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4049\/jimmunol.166.2.1009","article-title":"New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling","volume":"166","author":"Blunck","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0005-2736(97)00109-0","article-title":"Conformational studies of synthetic lipid A analogues and partial structures by infrared spectroscopy","volume":"1329","author":"Brandenburg","year":"1997","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.vaccine.2007.03.029_bib28","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1128\/IAI.70.11.6043-6047.2002","article-title":"The polysaccharide portion plays an indispensable role in Salmonella lipopolysaccharide-induced activation of NF-kappaB through human toll-like receptor 4","volume":"70","author":"Muroi","year":"2002","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.vaccine.2007.03.029_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1462-5822.2004.00387.x","article-title":"Human dendritic cell activation by Neisseria meningitidis: phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production","volume":"6","author":"Uronen-Hansson","year":"2004","journal-title":"Cell Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1462-5822.2005.00623.x","article-title":"Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function","volume":"8","author":"Steeghs","year":"2006","journal-title":"Cell Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.4049\/jimmunol.168.2.926","article-title":"Monophosphoryl lipid A activates both human dendritic cells and T cells","volume":"168","author":"Ismaili","year":"2002","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.03.029_bib32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","article-title":"The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells","volume":"12","author":"De Becker","year":"2000","journal-title":"Int Immunol"},{"issue":"20\u201321","key":"10.1016\/j.vaccine.2007.03.029_bib33","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/S0264-410X(99)00062-6","article-title":"The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1","volume":"17","author":"Moore","year":"1999","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2007.03.029_bib34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0264-410X(98)00259-X","article-title":"Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine","volume":"17","author":"Naess","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1084\/jem.103.2.225","article-title":"Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide","volume":"103","author":"Johnson","year":"1956","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.vaccine.2007.03.029_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1462-5822.2002.00214.x","article-title":"Expression of foreign LpxA acyltransferases in Neisseria meningitidis results in modified lipid A with reduced toxicity and retained adjuvant activity","volume":"4","author":"Steeghs","year":"2002","journal-title":"Cell Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2007.03.029_bib37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.0818-9641.2004.01285.x","article-title":"Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha\/beta","volume":"82","author":"Durand","year":"2004","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.029_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000233205","article-title":"Recent insight into class-specific properties of murine immunoglobulins obtained with the help of monoclonal antibodies","volume":"69","author":"Ovary","year":"1982","journal-title":"Int Arch Allergy Appl Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0022-1759(89)90156-7","article-title":"Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies","volume":"121","author":"Kenney","year":"1989","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2007.03.029_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/341073","article-title":"Conjugate vaccines against group B Streptococcus types IV and VII","volume":"186","author":"Paoletti","year":"2002","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2007.03.029_bib41","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/315285","article-title":"Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate","volume":"181","author":"Paoletti","year":"2000","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2007.03.029_bib42","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1086\/382193","article-title":"Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide\u2013protein conjugate vaccines","volume":"189","author":"Baker","year":"2004","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2007.03.029_bib43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ni1010","article-title":"Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways","volume":"4","author":"Hoebe","year":"2003","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.029_bib44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tim.2004.02.009","article-title":"Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2","volume":"12","author":"Miyake","year":"2004","journal-title":"Trends Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2007.03.029_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2007.03.029_bib46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/10408419891294216","article-title":"Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin)","volume":"24","author":"Kahler","year":"1998","journal-title":"Crit Rev Microbiol"},{"issue":"Pt 8","key":"10.1016\/j.vaccine.2007.03.029_bib47","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/00221287-147-8-2367","article-title":"gmhX, a novel gene required for the incorporation of l-glycero-d-manno-heptose into lipooligosaccharide in Neisseria meningitidis","volume":"147","author":"Shih","year":"2001","journal-title":"Microbiology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07003362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07003362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T06:27:21Z","timestamp":1587450441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07003362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":47,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0264410X07003362"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.03.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}